ORLADEYO® demonstrates strong patient retention1
- In just over a year following approval, more than 1000 prescriptions have been written1
- Almost half of patients currently on ORLADEYO were previously taking another prophylactic therapy, including injectable prophylaxis1
More than 75% of patients who started on ORLADEYO remained on therapy for 6 months or longer1,a
aData current as of March 2022.1
It’s important to set expectations with patients starting ORLADEYO
- The recommended dosage of ORLADEYO is one 150 mg capsule taken orally once daily with food2,b
- Ensure patients have rescue therapy available for treatment of breakthrough hereditary angioedema (HAE) attacks2
- Steady state of ORLADEYO is reached in 6 to 12 days, but it may take longer for patients to experience benefit2,3
- Encourage patients to check in frequently during the first few weeks of treatment4
b A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein or breast cancer resistance protein inhibitors (eg, cyclosporine).1
Many patients are starting—and staying on—ORLADEYO, including those who were previously on injectable prophylaxis.1